1 2 Summary 1 3
that satisfied our thresholds. Besides the published work (6,7), oligos have been designed for capturing several genomic 1 1 0 6 regions associated with Noonan Syndrome (8 genes), Type 1 Diabetes (9 genomic regions),
Crohn's Disease (10 genomic regions) and retinitis pigmentosa (37 genomic regions) (available 1 1 2 upon request). In each case the oligonucleotides performed well as observed by uniformity, 1 1 3 sensitivity and average depth of coverage [6, 7] . To additionally validate the tool, the MHC of a 1 1 4 random sample was captured and sequenced on the Illumina MiSeq. Alignment was performed 1 1 5
using COX as reference, since the sample showed a closer match to COX than PGF reference.
The average depth of coverage was estimated at 100x with 98.4% of positions >20X To capture sequence with acceptable range of accuracy and uniform representation across all the 1 2 5 regions in multiplexed reactions, oligonucleotides must meet certain specifications in terms of 1 2 6 sequence specificity, efficient oligo design with minimal interaction between the probes and 1 2 7 optimal process time [14, 16, 17, 26] . AnthOligo was implemented to satisfy these requirements
with the RSE method. It is well-understood that target capture design for multiplexed reactions is 1 2 9
an NP-complete problem [14, 27] . Heuristic optimization was necessary to process large regions, Although AnthOligo was developed to support the RSE method, its current abilities and can be used to target the MHC using CRISPR-Cas9, baits for gene panel analysis or even probes 1 4 1
for CgH array processes. AnthOligo is thus, a unique tool to an unaddressed domain and results 1 4 2
show that it achieves the desired objectives. Complete optimization problem.
4 7
Funding 1 4 8
The project described was supported by Award Number P30DK019525 from the National 
